Overview

Gender

male

Tim began his Oncology career with Bristol-Myers Squibb where he helped launch Taxol as an oncology sales professional. He held a variety of roles of increasing responsibility including Senior Director, Payer Marketing and Senior Director, Marketing. He joined Lilly Oncology in 2000. Among the roles Tim held at Lilly were West Area Sales Director and Growth Hormone Business Unit Leader. Tim eventually became the Vice President of the North America Oncology Business Unit at Lilly Oncology. In this role Tim lead the successful launch of Alimta and the co-sponsorship of the ImClone acquisition, at the time, the largest acquisition in the history of Lilly. Tim then moved to Europe and became the VP of International Oncology at Lilly. In this role, he oversaw all Oncology operations in Europe, Japan, and Australia. He led the successful launches of Cyramza in Europe and Japan. Tim then became the VP of Thoracic Product Development and Business Development. In this role, he led the successful FDA approval of Portraza as well as overseeing all business development opportunities. Tim eventually became the VP and COO for Lilly Oncology where he led the overall strategic direction of the oncology business unit.

Tim joined Athenex in July of 2018 as SVP of Global Oncology. In this role, he will lead the global launch efforts of oral paclitaxel and the rest of the innovative oncology pipeline.